Travere Therapeutics Inc (NAS:TVTX)
$ 6.34 -0.22 (-3.35%) Market Cap: 482.66 Mil Enterprise Value: 462.38 Mil PE Ratio: 0 PB Ratio: 6.54 GF Score: 58/100

Travere Therapeutics Inc FILSPARI in IgA Nephropathy Phase 3 PROTECT Study Results Call Transcript

Sep 21, 2023 / 12:30PM GMT
Release Date Price: $7.64 (-40.68%)
Operator

Good day, and welcome to the Travere Therapeutics Corporate Update Call. Today's conference call is being recorded. At this time, I would like to turn the conference call over to the Vice President of Investor Relations, Naomi Eichenbaum. Please go ahead, Naomi.

Naomi Eichenbaum

Thank you, Ruth, and thank you all for joining us today. Earlier today, we issued a press release announcing the confirmatory data from the Phase III PROTECT study of FILSPARI in IgA Nephropathy. A copy of the press release, along with the slides that we will be reviewing on today's call are available on the Investors section of our website.

Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Joining Eric will be our Chief Medical Officer, Dr. Jula Inrig and we are joined by guest speaker and key opinion leader, Dr. Brad Rovin, the Director of the Division of Nephrology at Ohio State University, Wexner Medical Center. Dr. Bill Rote, our Senior Vice President of Research and Development, will be available during the Q&A session.

Before we begin, I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot